MISSISSAUGA, ONTARIO--(Marketwired - Sep 18, 2014) -
Editors Note: There are three photos associated with this press release.
ZOLAR TECHNOLOGY & MFG CO. INC a leading manufacturer and distributor of dental diode lasers today announced that it has received a license from the Health Canada-Medical Device Bureau to sell its Photon dental soft-tissue diode laser systems with the Low Level Laser Therapy (LLLT) option throughout Canada. ZOLAR sells its products in Canada through the distributer, Oral Science.
Executive Officer Paul Atkins commented, "With the Photon diode laser now available with LLLT the dentist no longer has to purchase two separate devices to conduct soft tissue and dental pain therapy applications. The Photon now equipped with Low Level Laser Therapy option combines both applications in one unique device. This approval is an important milestone for ZOLAR as the Photon remains the only soft tissue diode laser on the market equipped with LLLT dental applications."
Joe Pal, Canada Sales Manager commented, "We are very excited to have received Health Canada Low Level Laser Therapy approval for our Photon soft tissue laser. We believe there is a strong demand for soft tissue dental diode laser incorporating LLLT. Some of the LLLT applications now available are: TMJ Protocols, Post Extraction, Dry Socket, Restorative, Root Sensitivity, Endodontic, Orthodontic, Implants, Soft Tissue Lesions and Scaling. We expect the Photon with LLLT to be a strong contributor to our continuing growth"
About Low Level Laser Therapy
Although low-level lasers are being used successfully in many dental clinics, the wide range of applications is still largely unknown to many practitioners, especially dental specialists. In these fields, there is the potential to see the most definitive results of what laser therapy can do to improve clinical outcomes and patient satisfaction. Photobiomodulation (PBM), also commonly referred to as Low-Level Laser Therapy (LLLT) or cold laser therapy uses light energy to elicit biological responses from the cell and normalize cell function.
Numerous studies have shown that PBM affects the mitochondria of the cell, primarily cytochrome-c oxidase in the electron transfer chain and porphyrins on the cell membrane. It has been proposed that when light photons are absorbed by these receptors, three events occur: stimulation of adenosine triphosphate (ATP) synthesis by activation of the electron transport chain; transient stimulation of reactive oxygen species, which increases the conversion of adenosine diphosphate (ADP) to ATP; and a temporary release of nitric oxide from its binding site on cytochrome-c oxidase. These factors contribute to the clinical effects seen with PBM, including tissue repair, relief of inflammation and pain, and repair of nerve damage.